Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 15 04:00PM ET
Dollar change
Percentage change
Index- P/E19.22 EPS (ttm)5.77 Insider Own3.34% Shs Outstand62.26M Perf Week-3.63%
Market Cap6.92B Forward P/E5.27 EPS next Y21.04 Insider Trans0.36% Shs Float60.26M Perf Month-6.25%
Income414.83M PEG4.93 EPS next Q4.20 Inst Own92.84% Short Float5.42% Perf Quarter-6.75%
Sales3.83B P/S1.80 EPS this Y3.80% Inst Trans-0.77% Short Ratio5.27 Perf Half Y-13.37%
Book/sh60.03 P/B1.85 EPS next Y10.83% ROA3.73% Short Interest3.26M Perf Year-23.91%
Cash/sh26.08 P/C4.25 EPS next 5Y3.90% ROE12.16% 52W Range110.42 - 147.14 Perf YTD-9.83%
Dividend Est.- P/FCF6.47 EPS past 5Y-3.53% ROI4.66% 52W High-24.62% Beta0.63
Dividend TTM- Quick Ratio1.74 Sales past 5Y15.52% Gross Margin72.78% 52W Low0.44% ATR (14)2.66
Dividend Ex-Date- Current Ratio2.12 EPS Y/Y TTM284.74% Oper. Margin17.20% RSI (14)31.15 Volatility2.19% 2.17%
Employees2800 Debt/Eq1.55 Sales Y/Y TTM4.78% Profit Margin10.82% Recom1.55 Target Price187.39
Option/ShortYes / Yes LT Debt/Eq1.38 EPS Q/Q135.40% Payout0.00% Rel Volume0.94 Prev Close110.58
Sales Surprise0.53% EPS Surprise-3.18% Sales Q/Q4.10% EarningsFeb 28 AMC Avg Volume619.06K Price110.91
SMA20-6.48% SMA50-8.49% SMA200-12.15% Trades Volume580,031 Change0.30%
Date Action Analyst Rating Change Price Target Change
Jan-03-24Initiated Robert W. Baird Outperform $160
Nov-27-23Downgrade UBS Buy → Neutral $170 → $135
Sep-29-23Initiated Raymond James Mkt Perform
Jun-12-23Resumed Wells Fargo Equal Weight $184 → $140
Dec-09-22Upgrade Goldman Neutral → Buy $192 → $190
Jun-14-22Initiated UBS Buy $194
Apr-06-22Downgrade Goldman Buy → Neutral $202 → $196
Nov-19-21Resumed Goldman Buy $198
Oct-07-21Resumed Jefferies Buy $172
Oct-05-21Initiated Citigroup Buy $200
Apr-10-24 07:45AM
Apr-04-24 09:15AM
Apr-02-24 07:30AM
Mar-29-24 11:30AM
Mar-28-24 10:15AM
10:15AM Loading…
Mar-20-24 10:15AM
Mar-18-24 03:28PM
Mar-17-24 08:50AM
Mar-14-24 12:00PM
Mar-13-24 02:25PM
Mar-12-24 05:34PM
Mar-09-24 11:15AM
Mar-07-24 01:51PM
01:10PM Loading…
Feb-29-24 10:45AM
Feb-28-24 06:30PM
Feb-27-24 10:15PM
Feb-24-24 05:06AM
Feb-23-24 09:15AM
Feb-21-24 08:50AM
05:00PM Loading…
Feb-20-24 05:00PM
Feb-14-24 04:15PM
Feb-13-24 10:15AM
Feb-09-24 09:15AM
Feb-07-24 07:35AM
Feb-03-24 05:06AM
Jan-31-24 03:33PM
Jan-22-24 05:16AM
Jan-18-24 05:37AM
Jan-13-24 05:06AM
Dec-28-23 10:06PM
Dec-22-23 12:07PM
Dec-21-23 04:17PM
Dec-20-23 04:15PM
Dec-08-23 01:20PM
Dec-01-23 09:02AM
Nov-30-23 07:45AM
Nov-29-23 11:15AM
Nov-28-23 08:48AM
Nov-27-23 09:49AM
Nov-15-23 05:21AM
Nov-14-23 12:50PM
Nov-09-23 05:07PM
Nov-08-23 07:00PM
Nov-07-23 12:33PM
Nov-01-23 04:15PM
Oct-31-23 05:42PM
Oct-30-23 04:05PM
Oct-26-23 11:40AM
Oct-25-23 04:15PM
Oct-23-23 07:45AM
Oct-21-23 06:38AM
Oct-20-23 10:30AM
Oct-18-23 07:55AM
Oct-17-23 09:55AM
Oct-16-23 07:45AM
Oct-13-23 08:15AM
Oct-10-23 11:40AM
Oct-06-23 10:15AM
Oct-04-23 02:58PM
Oct-02-23 05:21AM
Sep-30-23 05:06AM
Sep-27-23 02:38PM
Sep-22-23 11:57AM
Sep-21-23 05:41PM
Sep-20-23 02:15PM
Sep-19-23 06:45AM
Sep-13-23 04:15PM
Sep-12-23 07:30AM
Sep-11-23 07:45AM
Sep-08-23 11:30AM
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carr PatriciaSVP, Chief Accounting OfficerMar 07 '24Sale116.981,768206,8216,596Mar 08 06:07 PM
Carr PatriciaSVP, Chief Accounting OfficerMar 06 '24Sale119.641,936231,6288,364Mar 08 06:07 PM
Johnson Philip LEVP & Chief Financial OfficerMar 01 '24Buy119.6512,0001,435,80027,932Mar 05 07:28 PM
Cook Jennifer E.DirectorDec 04 '23Sale119.2741749,7366,888Dec 06 04:31 PM
Smith Mark DouglasDirectorDec 04 '23Sale119.2741749,7366,888Dec 06 04:39 PM
Patil Neena MEVP & Chief Legal OfficerSep 01 '23Sale144.251,500216,37529,186Sep 06 05:09 PM
Carr PatriciaSVP, Chief Accounting OfficerAug 29 '23Sale143.4714220,3735,986Aug 31 06:44 PM
Patil Neena MEVP & Chief Legal OfficerAug 15 '23Sale139.59750104,69530,686Aug 17 05:21 PM
McSharry Heather AnnDirectorAug 14 '23Sale138.161,344185,68516,778Aug 15 05:52 PM
Sohn Catherine A.DirectorAug 14 '23Sale138.161,241171,45514,868Aug 15 06:02 PM
ENRIGHT PATRICK GDirectorAug 14 '23Sale138.161,241171,45520,946Aug 15 05:45 PM
O'Keefe Kenneth WDirectorAug 14 '23Sale138.161,241171,45524,723Aug 15 07:49 PM
Winningham Rick EDirectorAug 14 '23Sale138.161,241171,45510,444Aug 15 06:08 PM
Gray PeterDirectorAug 14 '23Sale138.161,241171,45516,068Aug 15 05:47 PM
Cook Jennifer E.DirectorAug 14 '23Sale138.161,241171,4547,305Aug 15 05:44 PM
RIEDEL NORBERT GDirectorAug 14 '23Sale138.161,241171,45413,705Aug 15 05:58 PM
ORiordan AnneDirectorAug 14 '23Sale138.161,241171,45412,551Aug 15 07:51 PM
Smith Mark DouglasDirectorAug 14 '23Sale138.161,241171,4547,305Aug 15 06:00 PM
Carr PatriciaSVP, Chief Accounting OfficerAug 14 '23Sale138.1615821,8296,128Aug 15 05:43 PM
Mulligan SeamusDirectorJun 08 '23Option Exercise81.764,500367,9201,169,300Jun 12 04:47 PM
Carr PatriciaSVP, Chief Accounting OfficerJun 07 '23Sale127.9212616,1176,286Jun 09 04:55 PM
Patil Neena MEVP & Chief Legal OfficerJun 01 '23Sale127.981,600204,76332,826Jun 05 08:24 PM
GALA RENEE DEVP & Chief Financial OfficerMay 18 '23Sale131.756,000790,47435,978May 19 08:45 PM